Upcoming events – Nightstar's gene therapy and Alnylam's givosiran await key readouts
Nightstar hopes that early gene therapy data will give it a spark, while Alnylam awaits pivotal results for one of its biggest pipeline prospects, givosiran.
Upcoming events – Opdivo shoots for the liver, while Amicus seeks US guidance
Bristol-Myers Squibb should soon unveil data showing whether Opdivo’s liver cancer use could be broadened from second to first line, while Amicus investors look for a…
Go or no go? Roche, Lilly and Teva await big regulatory readouts
September promises at least eight notable US marketing decisions, including a crucial lung cancer ruling for Roche’s Tecentriq and verdicts on Lilly and Teva’s competing…
Upcoming events – Pivotal data readouts for Galapagos and Bayer
Galapagos and Bayer/Orion will both report phase III data this quarter – the former with filgotinib in arthritis and the latter with darolutamide in prostate cancer.
Upcoming events – US approval decision for Ionis and key trial readout for Intra-Cellular
Ionis seeks a green light for Waylivra in a rare disease, but safety concerns could seriously hit sales. Meanwhile, Intra-Cellular needs a pivotal bipolar trial win for…
Upcoming events – US approval verdicts for Opdivo and Galafold
The Bristol-Myers Squibb and Amicus drugs face approval decisions next week.
Upcoming events – Antibiotics from Insmed and Paratek face consecutive panels
Make-or-break FDA adcoms beckon for two antibiotics.
Upcoming events – FDA decisions loom for Alnylam and Pfizer
The companies hope that the US regulator approves patisiran and lorlatinib.
Upcoming events – FDA decision for Progenics and Allergy comes out of hiding
Progenics hopes to secure US approval for Azedra, while Allergy Therapeutics awaits phase III data with its birch vaccine.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.